Pelthos Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Pelthos Therapeutics Inc. (PTHS)
Company Research
Source: Yahoo! Finance
and net product revenue increased to $9.1M in Q4, with early-2026 momentum (5,297 units from Jan 1–Mar 6) and nearly 4,000 unique prescribers. Market access expanded via a PBM commercial contract covering ~20 million lives, driving coverage to 59% commercial and 99% Medicaid, while Q4 gross-to-net was 28.7% and is expected to rise into the mid- to high-30% range due to the PBM deal, co-pay cards and Medicaid mix. Pelthos bolstered liquidity with an $18M convertible note and a $50M term loan (drew $30M), improved Q4 net operating loss to $12M (adjusted EBITDA loss $9M), expects to reach profitability “toward the end of the year,” and acquired FDA-approved dermatology assets Xepi and Xeglyze with launches planned in 2027. Interested in Pelthos Therapeutics Inc.? Here are five stocks we like better. Pelthos Therapeutics (NYSEAMERICAN:PTHS) reported fourth-quarter and full-year 2025 results on its earnings call, highlighting rapid early demand for its lead product ZELSUVMI, two ne
Show less
Read more
Impact Snapshot
Event Time:
PTHS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTHS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTHS alerts
High impacting Pelthos Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
PTHS
News
- Pelthos Therapeutics Inc (PTHS) Q4 2025 Earnings Call Highlights: Prescription Surge and ... [Yahoo! Finance]Yahoo! Finance
- Pelthos Therapeutics Inc. (PTHS) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswire
- Pelthos Therapeutics to Present at 38th Annual ROTH Conference [Yahoo! Finance]Yahoo! Finance
- Pelthos Therapeutics to Present at 38th Annual ROTH ConferenceGlobeNewswire
PTHS
Earnings
- 3/19/26 - Miss
PTHS
Sec Filings
- 3/19/26 - Form 8-K
- 3/19/26 - Form 10-K
- 2/17/26 - Form SCHEDULE
- PTHS's page on the SEC website